Changing the Landscape

Millions of Americans suffer from central nervous system disorders. Tonix Pharmaceuticals is developing next-generation medicines to help.

Learn more

Latest News

Tonix Pharmaceuticals Presented New Clinical Results from Sub-Group Analysis of Phase 2 AtEase Study in Military-Related Posttraumatic Stress Disorder (PTSD)

• December 8, 2016 • 7:00 AM EST

Sub-Group Analysis of the Phase 2 AtEase Clinical Study Confirms TNX-102 SL’s Potential…

Read more

Management Team

Our experienced team has a strong track record of success in drug approvals and value creation.

View Management

Clinical Pipeline

Tonix's lead product candidate,TNX-102 SL, is being developed for the treatment of PTSD.

View Pipeline

About Tonix Pharmaceuticals

Tonix is developing next-generation medicines for common disorders of the central nervous system, with its lead program focusing on PTSD. This disorder is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and significant economic burden.

Learn more about tonix